Spero Biopharma

Prevention and Treatment of Alzheimer's Disease

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
Spero Biopharma
02/07/2022
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
01/01/2019
"1-10"

Spero Biopharma is the developer of Ladostigil, a drug designed to treat mild cognitive impairment before it progresses to Alzheimer's disease.